Search

Your search keyword '"Guarnotta G"' showing total 97 results

Search Constraints

Start Over You searched for: Author "Guarnotta G" Remove constraint Author: "Guarnotta G"
97 results on '"Guarnotta G"'

Search Results

1. Quality of information and appropriateness of Open AI outputs for lithiasis management

2. Role of body shape and metabolic syndrome in symptoms persistence in patients undergoing transurethral resection of the prostate

3. Quality of information and appropriateness of ChatGPT outputs for urological trauma

5. Major adverse cardiovascular events (MACE) related to phosphodiesterase 5 inhibitors (PDE5I): analysis of real-life data from eudra-vigilance (EV) database

6. Medications mostly associated with haematuria: assessment of the eudravigilance (EV) and food and drug administration (FDA) pharmacovigilance databases entries

7. Medications mostly associated with ejaculatory disorders: assessment of the eudravigilance (EV) and food and drug administration (FDA) pharmacovigilance databases entries

8. Is MRI and fusion biopsies necessary in patients with PSA levels >10 ng/ml?

9. Higher testosterone serum levels are associated with a higher childbirth in patients treated for testicular cancer

10. Role of post voided residual ratio in patients with detrusor underactivity: a pressure flow study analysis

11. Medications mostly associated with urinary tract infections (UTIS): assessment of the eudravigilance (EV) and food and drug administration (FDA) pharmacovigilance databases entries

17. Real-life adverse events related to PDE-5 I treatment: Analysis of the EudraVigilance database

18. Medications mostly associated with urinary retention: Assessment of the Eudravigilance (EV) and the Food and Drug Administration (FDA) Pharmacovigilance database entries

19. Cardiovascular adverse events-related to GnRH agonists and GnRH antagonists: Analysis of real-life data from Eudra-Vigilance database

20. Medications mostly associated with haematuria: Assessment of the EudraVigilance (EV) and Food and Drug Administration (FDA) Pharmacovigilance databases entries

21. Medications mostly associated with Urinary Tract Infections (UTIs): assessment of the EudraVigilance (EV) and Food and Drug Administration (FDA) Pharmacovigilance databases entries

22. Medications mostly associated with ejaculatory disorders: Assessment of the EudraVigilance (EV) and Food and Drug Administration (FDA) Pharmacovigilance databases entries

23. Role of inflammatory markers and frailty index as predictors of adverse pathological stage in patients with kidney cancer: a multicenter analysis

24. Role of inflammatory markers and frailty index as predictors of adverse pathological stage andcomplications in patients with upper urinary tract urothelial cancer: a multicenter analysis

25. Sexual adverse events-related to dutasteride e finasteride: analysis of real-life data from Eudra-Vigilance database

26. Sexual adverse events-related to dutasteride e finasteride: Analysis of real-life data from EudraVigilance database

27. Alpha-blockers adverse events: Analysis of real-life data from Eudra-Vigilance

29. Successful trial without catheter development of a clinical nomogram

31. Successful trial without catheter development of a clinical nomogram

33. Risk factors for acute urinary retention development of a clinical nomogram

35. SC113 - Medications mostly associated with urinary tract infections (UTIS): assessment of the eudravigilance (EV) and food and drug administration (FDA) pharmacovigilance databases entries

38. SC19 - Medications mostly associated with ejaculatory disorders: assessment of the eudravigilance (EV) and food and drug administration (FDA) pharmacovigilance databases entries

42. Using machine learning tools to predict prostate cancer upgrading after robotic radical prostatectomy

45. A0542 - Medications mostly associated with ejaculatory disorders: Assessment of the EudraVigilance (EV) and Food and Drug Administration (FDA) Pharmacovigilance databases entries

49. SC303 - Role of inflammatory markers and frailty index as predictors of adverse pathological stage in patients with kidney cancer: a multicenter analysis

50. SC135 - Role of inflammatory markers and frailty index as predictors of adverse pathological stage andcomplications in patients with upper urinary tract urothelial cancer: a multicenter analysis

Catalog

Books, media, physical & digital resources